Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:ENLV NASDAQ:GYRE NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$22.21-5.3%$19.75$89.95▼$99.05$643.76M0.9553,591 shs372,118 shsENLVEnlivex Therapeutics$0.72$0.89$0.66▼$2.10$170.32M1.49234,047 shs111,983 shsGYREGyre Therapeutics$6.06$7.21$5.97▼$11.61$587.99M2.0379,471 shs86,973 shsSLDBSolid Biosciences$6.62$7.45$2.72▼$8.87$651.74M2.471.18 million shs967,909 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-4.90%-11.09%+58.19%+215.93%ENLVEnlivex Therapeutics0.00%+2.90%-19.38%-37.61%-26.41%GYREGyre Therapeutics0.00%-5.90%-18.55%-27.86%-30.18%SLDBSolid Biosciences0.00%+1.69%-16.41%+7.12%+135.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$22.21-5.3%$19.75$89.95▼$99.05$643.76M0.9553,591 shs372,118 shsENLVEnlivex Therapeutics$0.72$0.89$0.66▼$2.10$170.32M1.49234,047 shs111,983 shsGYREGyre Therapeutics$6.06$7.21$5.97▼$11.61$587.99M2.0379,471 shs86,973 shsSLDBSolid Biosciences$6.62$7.45$2.72▼$8.87$651.74M2.471.18 million shs967,909 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-4.90%-11.09%+58.19%+215.93%ENLVEnlivex Therapeutics0.00%+2.90%-19.38%-37.61%-26.41%GYREGyre Therapeutics0.00%-5.90%-18.55%-27.86%-30.18%SLDBSolid Biosciences0.00%+1.69%-16.41%+7.12%+135.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AENLVEnlivex Therapeutics 2.00Hold$16.502,199.65% UpsideGYREGyre Therapeutics 2.00Hold$17.00180.53% UpsideSLDBSolid Biosciences 2.92Moderate Buy$16.36147.18% UpsideCurrent Analyst Ratings BreakdownLatest ENLV, SLDB, AVTE, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026SLDBSolid Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.00 ➝ $18.005/13/2026SLDBSolid Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.005/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026SLDBSolid Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026SLDBSolid Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.003/25/2026SLDBSolid Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/25/2026SLDBSolid Biosciences JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$11.00 ➝ $12.003/23/2026SLDBSolid Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/20/2026SLDBSolid Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.003/20/2026SLDBSolid Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AGYREGyre Therapeutics$116.59M5.04$0.22 per share27.27$1.41 per share4.30SLDBSolid BiosciencesN/AN/AN/AN/A$3.80 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/AENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/AGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)SLDBSolid Biosciences-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)Latest ENLV, SLDB, AVTE, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLDBSolid Biosciences-$0.40-$0.52-$0.12-$0.52N/AN/A3/19/2026Q4 2025SLDBSolid Biosciences-$0.51-$0.50+$0.01-$0.53N/AN/A3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78ENLVEnlivex TherapeuticsN/A193.24193.24GYREGyre TherapeuticsN/A4.644.06SLDBSolid BiosciencesN/A13.1013.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AENLVEnlivex Therapeutics1.02%GYREGyre Therapeutics23.99%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%ENLVEnlivex Therapeutics12.28%GYREGyre Therapeutics10.00%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableGYREGyre Therapeutics4097.03 million87.33 millionNo DataSLDBSolid Biosciences10098.45 million96.58 millionOptionableENLV, SLDB, AVTE, and GYRE HeadlinesRecent News About These CompaniesJ.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)May 24 at 1:14 PM | theglobeandmail.comWhere Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?May 20, 2026 | finance.yahoo.comSolid Biosciences (NASDAQ:SLDB) Lowered to "Strong Sell" Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12, 2026 | globenewswire.comSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyMay 7, 2026 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyApril 30, 2026 | globenewswire.comSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyApril 28, 2026 | markets.businessinsider.comSolid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist FinancialApril 28, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)April 17, 2026 | theglobeandmail.comSolid Biosciences Adjusts Board Classes in Governance MoveApril 12, 2026 | theglobeandmail.comSolid Biosciences to Participate at Upcoming Investor ConferencesApril 7, 2026 | globenewswire.comJ.P. Morgan Issues a Buy Rating on Solid Biosciences (SLDB)March 27, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Mereo Biopharma Group Plc (MREO)March 22, 2026 | theglobeandmail.comGuggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendationMarch 21, 2026 | msn.comSolid Bio wins new buy at Guggenheim on lead assetMarch 20, 2026 | msn.comSolid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 20, 2026 | finanznachrichten.deSolid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 19, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB)March 17, 2026 | theglobeandmail.comChardan Capital Issues a Buy Rating on Solid Biosciences (SLDB)March 13, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENLV, SLDB, AVTE, and GYRE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$22.21 -1.25 (-5.33%) As of 05/22/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Enlivex Therapeutics NASDAQ:ENLV$0.72 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.73 +0.01 (+1.46%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Gyre Therapeutics NASDAQ:GYRE$6.06 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.07 +0.01 (+0.17%) As of 05/22/2026 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Solid Biosciences NASDAQ:SLDB$6.62 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.63 +0.01 (+0.15%) As of 05/22/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
